These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26153442)

  • 1. In vitro functional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population.
    Dai DP; Hu LM; Geng PW; Wang SH; Cai J; Hu GX; Cai JP
    Xenobiotica; 2015; 45(11):1030-5. PubMed ID: 26153442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24.
    Lau PS; Leong KV; Ong CE; Dong AN; Pan Y
    Biochem Genet; 2017 Feb; 55(1):48-62. PubMed ID: 27578295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of CYP2C19 variants in nebivolol 4-hydroxlation in vitro.
    Zhou XY; Hu XX; Li MF; Wang H; Zhang LQ; Hu GX; Cai JP
    Drug Test Anal; 2018 May; 10(5):807-813. PubMed ID: 29098786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
    Wang H; An N; Wang H; Gao Y; Liu D; Bian T; Zhu J; Chen C
    Drug Metab Dispos; 2011 May; 39(5):830-7. PubMed ID: 21325430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Molecular and Enzyme Kinetic Basis for Altered Activity of Three Cytochrome P450 2C19 Variants Found in the Chinese Population.
    Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
    Curr Mol Pharmacol; 2020; 13(3):233-244. PubMed ID: 31713493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole.
    Lee SJ; Kim WY; Kim H; Shon JH; Lee SS; Shin JG
    Drug Metab Dispos; 2009 Nov; 37(11):2262-9. PubMed ID: 19661214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro.
    Fang P; He JY; Han AX; Lan T; Dai DP; Cai JP; Hu GX
    Pharmacology; 2017; 100(1-2):91-97. PubMed ID: 28494448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.
    Caraco Y; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1996 Oct; 60(4):396-404. PubMed ID: 8873687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
    Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
    Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
    J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype.
    Kamiya C; Inui N; Hakamata A; Miyakawa S; Tanaka S; Uchida S; Namiki N; Odagiri K; Watanabe H
    J Pharmacol Sci; 2019 Apr; 139(4):361-366. PubMed ID: 30902567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (-)-
    Cuypers ML; Chanteux H; Gillent E; Bonnaillie P; Saunders K; Beckers C; Delatour C; Dell'Aiera S; Ungell AL; Nicolaï J
    Drug Metab Dispos; 2020 Nov; 48(11):1121-1128. PubMed ID: 32839278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole.
    Jin SK; Kang TS; Eom SO; Kim JI; Lee HJ; Roh J
    J Clin Pharm Ther; 2009 Aug; 34(4):437-46. PubMed ID: 19583677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study.
    Zhou S; Xie R; Zhang X; He X; Huang J; Jungang Y; Liao M; Ding Y; Yang D; Liu Y; Zhang Q; Yang G; Liu F; Guan S; He Q; Lou H; Gong F; Meng X; Xiang Q; Zhao X; Cui Y
    Clin Transl Sci; 2022 Jun; 15(6):1439-1448. PubMed ID: 35235711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyp2c19 genotype and omeprazole hydroxylation phenotype in Chinese Li population.
    Wang JH; Li PQ; Fu QY; Li QX; Cai WW
    Clin Exp Pharmacol Physiol; 2007; 34(5-6):421-4. PubMed ID: 17439410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China.
    Chen L; Qin S; Xie J; Tang J; Yang L; Shen W; Zhao X; Du J; He G; Feng G; He L; Xing Q
    Pharmacogenomics; 2008 Jun; 9(6):691-702. PubMed ID: 18518848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease.
    Ma L; Yuan Y; Li J; Yu C; Zhao J
    Int J Immunogenet; 2020 Dec; 47(6):539-545. PubMed ID: 32862511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.